C3L-00893
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71.75633128
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.260
- HEME_METABOLISM+0.230
- NOTCH_SIGNALING+0.230
- TGF_BETA_SIGNALING+0.230
- PEROXISOME+0.200
- FATTY_ACID_METABOLISM+0.120
- CHOLESTEROL_HOMEOSTASIS+0.100
- MYOGENESIS+0.060
- ESTROGEN_RESPONSE_EARLY+0.050
- ADIPOGENESIS+0.040
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V1-0.570
- MYC_TARGETS_V2-0.550
- INTERFERON_ALPHA_RESPONSE-0.530
- MTORC1_SIGNALING-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02973 | — | cohortA1 | 0.928 |
| 2 | C3L-02958 | — | cohortA1 | 0.918 |
| 3 | TCGA-55-8097-01A-11R-2241-07 | — | cohortA1 | 0.911 |
| 4 | TCGA-55-8087-01A-11R-2241-07 | — | cohortA1 | 0.910 |
| 5 | TCGA-73-7498-01A-12R-2187-07 | — | cohortA2 | 0.900 |
| 6 | TCGA-69-7764-01A-11R-2170-07 | — | cohortA2 | 0.897 |
| 7 | TCGA-05-4384-01A-01R-1755-07 | — | cohortA2 | 0.871 |
| 8 | SRR6013544 | — | cohortA1 | 0.864 |
| 9 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.862 |
| 10 | TCGA-NJ-A7XG-01A-12R-A39D-07 | — | cohortA1 | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |